Difference between revisions of "Oligodendroglioma"

Jump to navigation Jump to search
(molecular testing necessary)
(→‎IHC: H3K27me3 -ve)
Line 151: Line 151:
*ATRX +ve (nuclear retention).
*ATRX +ve (nuclear retention).
**Useful for differentiating ''astrocytoma'' vs. ''oligodendroglioma''.<ref>{{Cite journal  | last1 = Reuss | first1 = DE. | last2 = Sahm | first2 = F. | last3 = Schrimpf | first3 = D. | last4 = Wiestler | first4 = B. | last5 = Capper | first5 = D. | last6 = Koelsche | first6 = C. | last7 = Schweizer | first7 = L. | last8 = Korshunov | first8 = A. | last9 = Jones | first9 = DT. | title = ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. | journal = Acta Neuropathol | volume = 129 | issue = 1 | pages = 133-46 | month = Jan | year = 2015 | doi = 10.1007/s00401-014-1370-3 | PMID = 25427834 }}</ref>
**Useful for differentiating ''astrocytoma'' vs. ''oligodendroglioma''.<ref>{{Cite journal  | last1 = Reuss | first1 = DE. | last2 = Sahm | first2 = F. | last3 = Schrimpf | first3 = D. | last4 = Wiestler | first4 = B. | last5 = Capper | first5 = D. | last6 = Koelsche | first6 = C. | last7 = Schweizer | first7 = L. | last8 = Korshunov | first8 = A. | last9 = Jones | first9 = DT. | title = ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. | journal = Acta Neuropathol | volume = 129 | issue = 1 | pages = 133-46 | month = Jan | year = 2015 | doi = 10.1007/s00401-014-1370-3 | PMID = 25427834 }}</ref>
*H3K27me3 +ve (nuclear loss).<ref>{{Cite journal  | last1 = Filipski | first1 = K. | last2 = Braun | first2 = Y. | last3 = Zinke | first3 = J. | last4 = Roller | first4 = B. | last5 = Baumgarten | first5 = P. | last6 = Wagner | first6 = M. | last7 = Senft | first7 = C. | last8 = Zeiner | first8 = PS. | last9 = Ronellenfitsch | first9 = MW. | title = Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. | journal = Acta Neuropathol | volume =  | issue =  | pages =  | month = May | year = 2019 | doi = 10.1007/s00401-019-02025-9 | PMID = 31065834 }}</ref>  
*H3K27me3 -ve (nuclear loss).<ref>{{Cite journal  | last1 = Filipski | first1 = K. | last2 = Braun | first2 = Y. | last3 = Zinke | first3 = J. | last4 = Roller | first4 = B. | last5 = Baumgarten | first5 = P. | last6 = Wagner | first6 = M. | last7 = Senft | first7 = C. | last8 = Zeiner | first8 = PS. | last9 = Ronellenfitsch | first9 = MW. | title = Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. | journal = Acta Neuropathol | volume =  | issue =  | pages =  | month = May | year = 2019 | doi = 10.1007/s00401-019-02025-9 | PMID = 31065834 }}</ref>  
*SOX10 +ve (up to 80%).<ref>{{Cite journal  | last1 = Bannykh | first1 = SI. | last2 = Stolt | first2 = CC. | last3 = Kim | first3 = J. | last4 = Perry | first4 = A. | last5 = Wegner | first5 = M. | title = Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. | journal = J Neurooncol | volume = 76 | issue = 2 | pages = 115-27 | month = Jan | year = 2006 | doi = 10.1007/s11060-005-5533-x | PMID = 16205963 }}</ref>
*SOX10 +ve (up to 80%).<ref>{{Cite journal  | last1 = Bannykh | first1 = SI. | last2 = Stolt | first2 = CC. | last3 = Kim | first3 = J. | last4 = Perry | first4 = A. | last5 = Wegner | first5 = M. | title = Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. | journal = J Neurooncol | volume = 76 | issue = 2 | pages = 115-27 | month = Jan | year = 2006 | doi = 10.1007/s11060-005-5533-x | PMID = 16205963 }}</ref>
*p53 -ve or low expressed.
*p53 -ve or low expressed.